中医药治疗非小细胞肺癌临床文献回顾性分析  

Literature review of the treatment of non-small cell lung cancer by traditional Chinese medicine

作　　者：姜家康[1] 王景春 姜庆辉 周云波 邹香妮[1] 迟文成[1] JIANG Jiakang;WANG Jingchun;JIANG Qinghui;ZHOU Yunbo;ZOU Xiangni;CHI Wencheng(Department of Oncology,First Affiliated Hospital,Heilongjiang University of Chinese Medicine,Harbin,Heilongjiang 150040;Heilongjiang University of Chinese Medicine,Harbin,Heilongjiang 150040)

机构地区：[1]黑龙江中医药大学附属第一医院肿瘤科,黑龙江哈尔滨150040 [2]黑龙江中医药大学,黑龙江哈尔滨150040

出　　处：《河北中医》2023年第1期133-138,共6页Hebei Journal of Traditional Chinese Medicine

基　　金：黑龙江省应用技术研究与开发计划项目(编号:GA17C010);黑龙江省自然科学基金面上项目(编号:H201478);黑龙江省中医药管理局课题项目(编号:ZHY16-120)。

摘　　要：目的通过对中医药治疗非小细胞肺癌的临床文献进行回顾性分析,阐明中医药治疗非小细胞肺癌的研究现状,为中医药治疗非小细胞肺癌的进一步研究提供客观的数据支撑。方法从中国知网、万方数据、维普中文期刊服务平台、PubMed、Cochrane Library数据库,检索2015年1月至2021年9月发表的关于中医药治疗非小细胞肺癌的临床文献,将符合条件文献中患者的样本量、年龄、性别、疗程、病情分布、诊断标准、分组原则、治疗原则、辨证分型、试验用药、疗效评估等方面的相关研究数据录入Excel表格,并进行整理分析。结果共纳入文献205篇,总样本量16603例,201篇文献提及性别分布,其中男9746例,女6647例,4篇文献未提及共计210例,患者年龄范围18~87周岁,疗程时间从10~90 d不等,138篇文献涉及非小细胞肺癌具体分型,样本量为11707例,其中腺癌数量最多,共6062例(51.8%),192篇文献描述了随机序号的产生方法,其余13篇文献只是标明了“对照组”,205篇文献中均采用了联合治疗研究,其中中药联合化疗最多,共168篇(82.0%)。205篇文献均按照诊断标准严格纳入,均列出了详细的疗效评价标准,结果显示临床有效率大于50%共110篇(53.7%),其中大于90%共10篇(4.9%)。205篇文献中共有120篇文献进行了辨证分型方面的报道,涉及证型16种,出现总频次176次,其中气阴两虚证出现频次最多,共61次(34.7%),肺脾气虚证次之,共19次(10.8%)。205篇文献中共出现208味中药,累计用药频次2390次,其中黄芪的出现频次最高,共129次(5.4%),其次是甘草127次(5.3%)、白术105次(4.4%)。将208味中药以2012年版《中药学》教材和2020版《中华人民共和国药典》作为标准,略去未记录的24味中药(累计频次86次),对剩余184味(累计频次2304次)进行归类分析,味数方面以补气药、滋阴药、补血药、补阳药组成的补虚药味数最多,合计39味(21.2%),用药频�Objective To clarify the current research status of non-small cell lung cancer(NSCLC)treatment by traditional Chinese medicine(TCM)through literature review,thus providing objective references for TCM treatment of NSCLC in clinical practice.Methods Articles about TCM treatment of NSCLC published from January 2015 to September 2021 were searched in online databases,including the China National Knowledge Infrastructure(CNKI),Wanfang Data,CQVIP,PubMed and Cochrane Library.Sample size,age,sex,course of treatment,disease distribution,diagnostic criteria,grouping principle,treatment principle,syndrome differentiation and classification,experimental drug use,and efficacy evaluation were extracted from eligible literatures and introduced into Excel for analysis.Results A total of 205 eligible articles were included,with a total sample size of 16603 cases.Totally 201 articles mentioned gender distribution,including 9746 males and 6647 females,and 4 articles did not mention gender distribution in a total of 210 cases.The age of NSCLC patients ranged from 18 to 87 years old,and the course of treatment ranged from 10 to 90 days.Totally 138 articles described the classification of NSCLC in 11707 cases,of which 6062 cases(51.8%)were adenocarcinomas.Totally 192 articles described the grouping using a random number,and the remaining 13 articles only mentioned the control group.A combination therapy was given in all the 205 articles,among which the combination of chemotherapy and TCM treatment was the most,with 168 articles(82.0%).All 205 articles described the strict recruitment of NSCLC patients according to the diagnostic criteria,and all listed the detailed evaluation criteria of curative effect.The results showed that the clinical effective rate was over 50%in 110 articles(53.7%),of which,a higher than 90%was mentioned in 10 articles(4.9%).A total of 120 articles reported the syndrome differentiation and classification of NSCLC,involving 16 types of syndromes,with a total frequency of 176 times.Among them,deficiency of both

关 键 词：非小细胞肺癌 中医疗法 回顾性分析 

分 类 号：R289.6[医药卫生—方剂学]